[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 50.16.107.222. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
December 1, 1993

Silicone Gel Breast Implants

Author Affiliations

(Vice-Chair), Jacksonville, Fla; (Chairman), Durham, NC; (Resident Representative), Tucker, Ga; Beverly Hills, Calif; Minneapolis, Minn; Syracuse, NY; Tucson, Ariz; Macon, Ga; Cleveland, Ohio; New Orleans, La; (Medical Student Representative), New York, NY; Baltimore, Md
From the Council on Scientific Affairs, American Medical Association, Chicago, III.

JAMA. 1993;270(21):2602-2606. doi:10.1001/jama.1993.03510210088033
Abstract

AT THE 1991 Annual Meeting, Resolution 259 was referred by the Board of Trustees to the Council on Scientific Affairs (CSA) for a report on the evaluation of the safety of breast implants. The recommendations of Report M prepared by the CSA were adopted as amended by the American Medical Association (AMA) House of Delegates at the Interim Meeting in 1991 in lieu of Resolution 259 (A-91) and Resolution 521 (I-91) and the remainder of the Report was filed (Policy 525.984, AMA Policy Compendium). Report M described the Food and Drug Administration (FDA) regulatory history of breast implant devices through August 1991. Because of continuing developments, including a voluntary moratorium on their use by the FDA in November 1991, the Council elected to provide a follow-up report (Report C) on this subject. Report C covers the continuing FDA regulatory history through October 1992 and

See also pp 2607 and 2608.

×